- Home
- RSVR vs LXRX Comparison
RSVR vs LXRX Comparison
Compare RSVR & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSVR
- LXRX
- Stock Information
- Founded
- RSVR 2007
- LXRX 1995
- Country
- RSVR United States
- LXRX United States
- Employees
- RSVR N/A
- LXRX N/A
- Industry
- RSVR Movies/Entertainment
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- RSVR Consumer Discretionary
- LXRX Health Care
- Exchange
- RSVR Nasdaq
- LXRX Nasdaq
- Market Cap
- RSVR 504.1M
- LXRX 428.8M
- IPO Year
- RSVR N/A
- LXRX 2000
- Fundamental
- Price
- RSVR $7.93
- LXRX $1.12
- Analyst Decision
- RSVR Strong Buy
- LXRX Buy
- Analyst Count
- RSVR 1
- LXRX 5
- Target Price
- RSVR $11.50
- LXRX $3.23
- AVG Volume (30 Days)
- RSVR 55.3K
- LXRX 1.6M
- Earning Date
- RSVR 10-29-2025
- LXRX 11-11-2025
- Dividend Yield
- RSVR N/A
- LXRX N/A
- EPS Growth
- RSVR N/A
- LXRX N/A
- EPS
- RSVR 0.12
- LXRX N/A
- Revenue
- RSVR $161,553,186.00
- LXRX $58,432,000.00
- Revenue This Year
- RSVR $7.17
- LXRX N/A
- Revenue Next Year
- RSVR $5.00
- LXRX N/A
- P/E Ratio
- RSVR $68.72
- LXRX N/A
- Revenue Growth
- RSVR 9.65
- LXRX 1504.83
- 52 Week Low
- RSVR $6.56
- LXRX $0.28
- 52 Week High
- RSVR $9.83
- LXRX $2.18
- Technical
- Relative Strength Index (RSI)
- RSVR 53.96
- LXRX 50.98
- Support Level
- RSVR $7.75
- LXRX $1.03
- Resistance Level
- RSVR $8.03
- LXRX $1.19
- Average True Range (ATR)
- RSVR 0.16
- LXRX 0.06
- MACD
- RSVR 0.00
- LXRX -0.00
- Stochastic Oscillator
- RSVR 67.65
- LXRX 52.94
About RSVR Reservoir Media Inc.
Reservoir Media Inc is an independent music company. It operates a music publishing business, a recorded music business, a management business, and a rights management entity in the Middle East. The company's segments include Music Publishing and Recorded Music. It generates the maximum of its revenue from the Music Publishing segment.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.